128.97

0.46% -0.59

Pre-market: 128.92 -0.05 -0.04%

Illumina Inc (ILMN)

Overview News Price History Option Chain Financials Why ILMN Down? Discussions Forecast Stock Split

Illumina Inc stock is traded at $128.97, with a volume of 1.31M. It is down -0.46% in the last 24 hours and down -3.89% over the past month. Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Previous Close:

$129.56

Open:

$130.895

24h Volume:

1.31M

Relative Volume:

0.66

Market Cap:

$19.72B

Revenue:

$4.29B

Net Income/Loss:

$703.00M

P/E Ratio:

28.89

EPS:

4.4635

Net Cash Flow:

$993.00M

1W Performance:

+5.83%

1M Performance:

-3.89%

6M Performance:

+32.03%

1Y Performance:

+51.93%

1-Day Range:

$128.60

$132.28

1-Week Range:

$118.53

$134.76

52-Week Range:

$68.70

$155.53

Illumina Inc Stock (ILMN) Company Profile

Name

Illumina Inc

Sector

Healthcare (1106)

Industry

Diagnostics & Research (52)

Phone

(858) 202-4500

Address

5200 ILLUMINA WAY, SAN DIEGO, CA

Employee

8,650

Twitter

@illumina

Next Earnings Date

2024-11-07

Latest SEC Filings

ILMN's Discussions on Twitter

Compare ILMN vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ILMN Illumina Inc	128.97	19.81B	4.29B	703.00M	993.00M	4.4635
TMO Thermo Fisher Scientific Inc	512.69	190.90B	44.56B	6.73B	6.29B	17.74
DHR Danaher Corp	204.73	144.26B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	648.70	50.60B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	120.54	33.67B	6.95B	1.30B	1.15B	4.5696
WAT Waters Corp	319.04	30.62B	3.17B	642.63M	516.49M	10.77

Illumina Inc Stock (ILMN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-12-25	Downgrade	Daiwa Securities	Outperform → Neutral
Jul-11-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Mar-04-25	Reiterated	Citigroup	Neutral
Feb-28-25	Downgrade	HSBC Securities	Buy → Hold
Feb-10-25	Downgrade	Barclays	Equal Weight → Underweight
Feb-07-25	Downgrade	TD Cowen	Buy → Hold
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Nov-12-24	Resumed	Morgan Stanley	Equal-Weight
Oct-17-24	Upgrade	HSBC Securities	Hold → Buy
Aug-28-24	Upgrade	Argus	Hold → Buy
Aug-16-24	Upgrade	Daiwa Securities	Neutral → Buy
Aug-14-24	Upgrade	Barclays	Underweight → Equal Weight
Aug-14-24	Upgrade	TD Cowen	Hold → Buy
Jul-10-24	Upgrade	Citigroup	Neutral → Buy
Jun-03-24	Resumed	Jefferies	Hold
Jan-16-24	Downgrade	HSBC Securities	Buy → Hold
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform
Dec-18-23	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Dec-15-23	Upgrade	Bernstein	Underperform → Mkt Perform
Dec-14-23	Initiated	Guggenheim	Buy
Dec-14-23	Initiated	Stephens	Overweight
Dec-13-23	Initiated	Wolfe Research	Outperform
Dec-12-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-11-23	Upgrade	Citigroup	Sell → Neutral
Nov-10-23	Downgrade	Canaccord Genuity	Buy → Hold
Sep-28-23	Initiated	Bernstein	Underperform
Jul-05-23	Resumed	JP Morgan	Neutral
Jan-25-23	Downgrade	Argus	Buy → Hold
Jan-05-23	Initiated	Scotiabank	Sector Perform
Dec-12-22	Downgrade	Citigroup	Neutral → Sell
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Oct-04-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-28-22	Upgrade	Evercore ISI	In-line → Outperform
Aug-25-22	Initiated	Credit Suisse	Neutral
Jul-13-22	Downgrade	Barclays	Equal Weight → Underweight
Jan-18-22	Upgrade	Stifel	Hold → Buy
Jan-11-22	Upgrade	Barclays	Underweight → Equal Weight
Jan-07-22	Upgrade	BofA Securities	Underperform → Neutral
Jan-06-22	Resumed	Morgan Stanley	Equal-Weight
Jan-06-22	Resumed	Piper Sandler	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Aug-19-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-01-21	Upgrade	Evercore ISI	Underperform → In-line
Mar-31-21	Downgrade	Atlantic Equities	Overweight → Neutral
Mar-31-21	Upgrade	Canaccord Genuity	Hold → Buy
Mar-03-21	Initiated	Barclays	Underweight
Dec-22-20	Upgrade	Piper Sandler	Neutral → Overweight
Dec-17-20	Upgrade	BTIG Research	Neutral → Buy
Oct-13-20	Downgrade	Guggenheim	Buy → Neutral
Sep-30-20	Initiated	Atlantic Equities	Overweight
Sep-29-20	Downgrade	Wolfe Research	Outperform → Peer Perform
Sep-22-20	Downgrade	Stifel	Buy → Hold
Sep-22-20	Downgrade	UBS	Buy → Neutral
Sep-21-20	Upgrade	Guggenheim	Neutral → Buy
Sep-21-20	Downgrade	JP Morgan	Overweight → Neutral
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Aug-07-20	Downgrade	Evercore ISI	In-line → Underperform
Aug-07-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Downgrade	Guggenheim	Buy → Neutral
Apr-24-20	Downgrade	Citigroup	Buy → Neutral
Apr-21-20	Downgrade	Robert W. Baird	Outperform → Neutral
Jan-08-20	Initiated	Wells Fargo	Underweight
Jan-07-20	Initiated	Citigroup	Buy
Jan-02-20	Downgrade	Evercore ISI	Outperform → In-line
Nov-15-19	Initiated	Stifel	Buy
Oct-25-19	Initiated	Guggenheim	Buy

View All

Illumina Inc Stock (ILMN) Latest News

04:00 AM

ARK Investment Management LLC Has $139.41 Million Position in Illumina, Inc. $ILMN - MarketBeat

04:00 AM

Mar 04, 2026

Why Illumina (ILMN) is a Top Growth Stock for the Long-Term - Nasdaq

Mar 04, 2026

DNA Microarray Market is expected to reach US$ 6.12 billion - openPR.com

Mar 04, 2026

Mar 03, 2026

Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Mar 03, 2026

ILMN: Sequencing innovation, clinical growth, and end-to-end solutions drive strong outlook - TradingView

Mar 03, 2026

Is Illumina’s (ILMN) TruPath Rare Disease Push Reframing Its Clinical Sequencing Investment Narrative? - simplywall.st

Mar 02, 2026

Illumina Inc. stock underperforms Monday when compared to competitors - MarketWatch

Mar 02, 2026